Non-fucosylated Anti-Human PD-L1 (Durvalumab) Therapeutic Antibody (CAT#: BioBet-049ZP) Datasheet

CD274

CD274 molecule

This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and nonhematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin Vlike and Clike domains. Interaction of this ligand with its receptor inhibits Tcell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic Tcell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.

B7-H, B7H1, PDL1, PD-L1, PDCD1L1, PDCD1LG1

Plasma membrane, Endosome

Diseases associated with CD274 include Testicular Lymphoma and Smoldering Myeloma.

Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.

1.It plays a key role in inducing and maintaining immune tolerance to oneself (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, it regulates the activation threshold of t cells and limits the effector response of t cells (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through an unknown activation receptor, it is possible to stimulate a subset of T cells to mainly produce interleukin 10 (IL10) (PubMed: 10581077). 2. Tumors use the pdcd1 mediated inhibitory pathway to weaken anti-tumor immunity and escape the destruction of the immune system, thereby promoting tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits the effector function of cytotoxic T lymphocytes (CTLs) (similar). The blockade of the pdcd1 mediated pathway leads to the reversal of the exhausted T cell phenotype and the normalization of the anti-tumor response, which provides a theoretical basis for cancer immunotherapy (through similarity).

1.Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. 2.Glycosylation at Asn35, Asn192, Asn200, and Asn219 3.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Durvalumab

Human

Human

Durvalumab is a human immunoglobulin G1κ (IgG1κ) monoclonal antibody and is known as a checkpoint inhibitor drug. It was developed by Medimmune / AstraZeneca and was used for immunotherapy of previously treated patients with locally advanced or metastatic cancer of the urinary system.

Urothelial carcinoma ureter metastatic
Locally advanced Urothelial Carcinoma

MEDI4736

Durvalumab is a human immunoglobulin G1κ (IgG1k) monoclonal antibody that blocks the binding of PD-L1 to PD-1 and CD80. PD1 signaling pathway can physiologically limit the activity of T cells and generate autoimmune or inflammatory responses in the body, which is the mechanism by which tumor cells develop immune resistance. Durvalumab-mediated blocking of the PD1 pathway further enhances T cell activation, effector T cell proliferation, NK cell activity, and cytokine production, thereby minimizing local progression or the growth of metastatic solid tumors.

Urothelial carcinoma ureter metastatic
Locally advanced Urothelial Carcinoma